AlaskaAngel
07-14-2006, 08:10 PM
Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer
This study is currently recruiting patients.
Verified by Fresenius Biotech GmbH April 2006
Sponsored by:Fresenius Biotech GmbH
Information provided by:Fresenius Biotech GmbH
ClinicalTrials.gov Identifier:NCT00351858
http://www.clinicaltrials.gov/html/images/arrow2.gif Purpose
The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer
This study is currently recruiting patients.
Verified by Fresenius Biotech GmbH April 2006
Sponsored by:Fresenius Biotech GmbH
Information provided by:Fresenius Biotech GmbH
ClinicalTrials.gov Identifier:NCT00351858
http://www.clinicaltrials.gov/html/images/arrow2.gif Purpose
The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer